159 related articles for article (PubMed ID: 27250926)
1. Probiotic yeast Saccharomyces boulardii (nom. nud.) modulates adhesive properties of Candida glabrata.
Tomičić Z; Zupan J; Matos T; Raspor P
Med Mycol; 2016 Nov; 54(8):835-45. PubMed ID: 27250926
[TBL] [Abstract][Full Text] [Related]
2. Influence of culture conditions on co-aggregation of probiotic yeast Saccharomyces boulardii with Candida spp. and their auto-aggregation.
Tomičić R; Tomičić Z; Raspor P
Folia Microbiol (Praha); 2022 Jun; 67(3):507-515. PubMed ID: 35169980
[TBL] [Abstract][Full Text] [Related]
3. In vitro modulation of probiotic bacteria on the biofilm of Candida glabrata.
Chew SY; Cheah YK; Seow HF; Sandai D; Than LT
Anaerobe; 2015 Aug; 34():132-8. PubMed ID: 26028405
[TBL] [Abstract][Full Text] [Related]
4. Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
Keniya MV; Ruma YN; Tyndall JDA; Monk BC
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126959
[TBL] [Abstract][Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
7. Probiotic Yeasts Inhibit Virulence of Non
Kunyeit L; Kurrey NK; Anu-Appaiah KA; Rao RP
mBio; 2019 Oct; 10(5):. PubMed ID: 31615960
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Chen TC; Chen YH; Chen YC; Lu PL
Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
[TBL] [Abstract][Full Text] [Related]
9. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
Skrodeniene E; Dambrauskiene A; Vitkauskiene A
Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
[TBL] [Abstract][Full Text] [Related]
10. Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species.
Nagayoshi Y; Miyazaki T; Shimamura S; Nakayama H; Minematsu A; Yamauchi S; Takazono T; Nakamura S; Yanagihara K; Kohno S; Mukae H; Izumikawa K
PLoS One; 2017; 12(7):e0180990. PubMed ID: 28700656
[TBL] [Abstract][Full Text] [Related]
11. Growth, survival, and metabolic activities of probiotics Lactobacillus rhamnosus GG and Saccharomyces cerevisiae var. boulardii CNCM-I745 in fermented coffee brews.
Chan MZA; Toh M; Liu SQ
Int J Food Microbiol; 2021 Jul; 350():109229. PubMed ID: 34023682
[TBL] [Abstract][Full Text] [Related]
12. Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 exhibit strong antifungal effects against vulvovaginal candidiasis-causing Candida glabrata isolates.
Chew SY; Cheah YK; Seow HF; Sandai D; Than LT
J Appl Microbiol; 2015 May; 118(5):1180-90. PubMed ID: 25688886
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
Martín E; Parras P; Lozano MC
Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
[TBL] [Abstract][Full Text] [Related]
14. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
15. Probiotics and prevention of Clostridium difficile infection.
Goldstein EJC; Johnson SJ; Maziade PJ; Evans CT; Sniffen JC; Millette M; McFarland LV
Anaerobe; 2017 Jun; 45():114-119. PubMed ID: 27988389
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
17. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.
Sojakova M; Liptajova D; Borovsky M; Subik J
Mycopathologia; 2004 Feb; 157(2):163-9. PubMed ID: 15119851
[TBL] [Abstract][Full Text] [Related]
18. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
[TBL] [Abstract][Full Text] [Related]
19. Determination of MICING: a new assay for assessing minimal inhibitory concentration for invasive growth.
Zupan J; Tomičić Z; Raspor P
Eur J Clin Microbiol Infect Dis; 2015 May; 34(5):1023-30. PubMed ID: 25620781
[TBL] [Abstract][Full Text] [Related]
20. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).
Safdar A; Chaturvedi V; Koll BS; Larone DH; Perlin DS; Armstrong D
Antimicrob Agents Chemother; 2002 Oct; 46(10):3268-72. PubMed ID: 12234857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
